Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH Subprotocol N: GSK2636771 in PTEN Mutated/Deleted Tumors
NCT04439149Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of GSK-2636771 in malignant solid neoplasm, lymphoma, hematopoietic and lymphoid cell neoplasm, multiple myeloma (MM), sponsored by National Cancer Institute. Started May 2016; status: active, not recruiting.
02
Drugs
GSK-2636771
03
Conditions
malignant solid neoplasmlymphomahematopoietic and lymphoid cell neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439149.